Oncology review☆

unknown said:

This comment has been removed by the Moderator

The upsc 2009 report
Pat, could you re-email that to me?
My old email is no longer accessible.
New one
madisonraygallery@yahoo.com

barb55 said:

The transcript costs $31.50 through science direct. It is protected and yes, I would like to avoid breaking any law by posting it. I've been out of town and still haven't read through it all. Any thoughts folks?
Barb

please don't get into trouble!
I think you should (when you have time), read through it and maybe just post on here a synopsis. Like just share the pertinent stuff. I am sure it is really long and probably a lot of stuff wordy technical stuff in it. I definately don't think you should post it on here! I am good with whatever you decide. You have provided us with the link to purchase the document if we want to. I certainly appreciate that. I may check with my doctor to make sure he is aware the information is available. Thanks Barb.

MoeKay said:

Possible Options
If you live near a medical school, the journal Gynecologic Oncology would be available in hard copy in the medical school library. You can discuss the library's copying policies and fees with a research librarian. I recall making a copy of journal articles for my informational and educational purposes for a dime a page after my endometrial cancer diagnosis in 1999.

Another option would be to contact the corresponding author on the first page of the journal, which provides his name and email address, and explain the situation. He may be willing to make educational copies available to other UPSC cancer survivors.

Good luck!

MoeKay

My notes from this article:
I read the 12-page article, and will share my notes. There were many mortality and survival statistics, but I will not share those as the data was extrapolated from all published scientific study results from January 1966 to May 2009, and factoring in those old stats really skews the results downward, in my opinion. But there was some good information in this article:

UPSC women are typically:
older and thinner than other endometrial cancer patients,
& less likely to have hormonal risk factors than other endometrial; cancer patients;
& more likely to have BRCA gene;
More likely to have taken Tamoxifen if they had breast cancer prior to UPSC;
More likely to have P53 mutation; and
& more likely to have HER-2/neu gene amplification. The HER-2 predicts a poorer prognosis, but does open up the possibility of targeted molecular therapies.

Treatment protocols for ovarian serous cancer should be looked at for UPSC recurrences. Adriamycin, cytoxan, & cisplatin bought an average 7 months of remission for recurrent OVARIAN serous cancer women.

Current 'gold standard' for recurrent UPSC:
1.) surgery to reduce residual disease to less than 2 CM.
2.) TAP (paciltaxel + cisplatin + doxorubicin
3.) tumor-directed radiation
This 'gold standard' does not increase recurrence-free survival, but DOES increase progression free survival by 8.3 months. It has a high rate of neurotoxicity.

Sandwiched radiation has been shown to be statistically better than radiation-then-chemo, or chemo-then-radiation.

UPSC women with CA-125s greater than 35 BEFORE surgery have 3.7 times greater risk of cancer-related death than those with CA-125s under 35 before surgery. (Good news for those of you who have always had low CA-125s. Not so good for us that had tp bring our CA-125s down with chemo.)

Indicators in addition to CA-125s that could/should be looked at in the future for UPSC include serum markers like HE4 (a soluble mesothelin-related peptide) and YKL-40 (a secreted glycolprotein).

Herceptin has not yet been studied for UPSC women with HER2, but looks promising.

The article recommended an 'international rare cancer cooperative network' study of UPSC.

lindaprocopio said:

My notes from this article:
I read the 12-page article, and will share my notes. There were many mortality and survival statistics, but I will not share those as the data was extrapolated from all published scientific study results from January 1966 to May 2009, and factoring in those old stats really skews the results downward, in my opinion. But there was some good information in this article:

UPSC women are typically:
older and thinner than other endometrial cancer patients,
& less likely to have hormonal risk factors than other endometrial; cancer patients;
& more likely to have BRCA gene;
More likely to have taken Tamoxifen if they had breast cancer prior to UPSC;
More likely to have P53 mutation; and
& more likely to have HER-2/neu gene amplification. The HER-2 predicts a poorer prognosis, but does open up the possibility of targeted molecular therapies.

Treatment protocols for ovarian serous cancer should be looked at for UPSC recurrences. Adriamycin, cytoxan, & cisplatin bought an average 7 months of remission for recurrent OVARIAN serous cancer women.

Current 'gold standard' for recurrent UPSC:
1.) surgery to reduce residual disease to less than 2 CM.
2.) TAP (paciltaxel + cisplatin + doxorubicin
3.) tumor-directed radiation
This 'gold standard' does not increase recurrence-free survival, but DOES increase progression free survival by 8.3 months. It has a high rate of neurotoxicity.

Sandwiched radiation has been shown to be statistically better than radiation-then-chemo, or chemo-then-radiation.

UPSC women with CA-125s greater than 35 BEFORE surgery have 3.7 times greater risk of cancer-related death than those with CA-125s under 35 before surgery. (Good news for those of you who have always had low CA-125s. Not so good for us that had tp bring our CA-125s down with chemo.)

Indicators in addition to CA-125s that could/should be looked at in the future for UPSC include serum markers like HE4 (a soluble mesothelin-related peptide) and YKL-40 (a secreted glycolprotein).

Herceptin has not yet been studied for UPSC women with HER2, but looks promising.

The article recommended an 'international rare cancer cooperative network' study of UPSC.

Linda thanks again for sharing
I always appreciate you research summaries. let's hope we don't have a reoccurence very soon. You are such an inspirtation to all of us. Thanks again. In peace and caring. HUGS to you.

lindaprocopio said:

My notes from this article:
I read the 12-page article, and will share my notes. There were many mortality and survival statistics, but I will not share those as the data was extrapolated from all published scientific study results from January 1966 to May 2009, and factoring in those old stats really skews the results downward, in my opinion. But there was some good information in this article:

UPSC women are typically:
older and thinner than other endometrial cancer patients,
& less likely to have hormonal risk factors than other endometrial; cancer patients;
& more likely to have BRCA gene;
More likely to have taken Tamoxifen if they had breast cancer prior to UPSC;
More likely to have P53 mutation; and
& more likely to have HER-2/neu gene amplification. The HER-2 predicts a poorer prognosis, but does open up the possibility of targeted molecular therapies.

Treatment protocols for ovarian serous cancer should be looked at for UPSC recurrences. Adriamycin, cytoxan, & cisplatin bought an average 7 months of remission for recurrent OVARIAN serous cancer women.

Current 'gold standard' for recurrent UPSC:
1.) surgery to reduce residual disease to less than 2 CM.
2.) TAP (paciltaxel + cisplatin + doxorubicin
3.) tumor-directed radiation
This 'gold standard' does not increase recurrence-free survival, but DOES increase progression free survival by 8.3 months. It has a high rate of neurotoxicity.

Sandwiched radiation has been shown to be statistically better than radiation-then-chemo, or chemo-then-radiation.

UPSC women with CA-125s greater than 35 BEFORE surgery have 3.7 times greater risk of cancer-related death than those with CA-125s under 35 before surgery. (Good news for those of you who have always had low CA-125s. Not so good for us that had tp bring our CA-125s down with chemo.)

Indicators in addition to CA-125s that could/should be looked at in the future for UPSC include serum markers like HE4 (a soluble mesothelin-related peptide) and YKL-40 (a secreted glycolprotein).

Herceptin has not yet been studied for UPSC women with HER2, but looks promising.

The article recommended an 'international rare cancer cooperative network' study of UPSC.

Thank You
Thanks for your help with this document. You have great skill at summarizing. I live in a rural area with few resources locally and appreciate this group.

lindaprocopio said:

My notes from this article:
I read the 12-page article, and will share my notes. There were many mortality and survival statistics, but I will not share those as the data was extrapolated from all published scientific study results from January 1966 to May 2009, and factoring in those old stats really skews the results downward, in my opinion. But there was some good information in this article:

UPSC women are typically:
older and thinner than other endometrial cancer patients,
& less likely to have hormonal risk factors than other endometrial; cancer patients;
& more likely to have BRCA gene;
More likely to have taken Tamoxifen if they had breast cancer prior to UPSC;
More likely to have P53 mutation; and
& more likely to have HER-2/neu gene amplification. The HER-2 predicts a poorer prognosis, but does open up the possibility of targeted molecular therapies.

Treatment protocols for ovarian serous cancer should be looked at for UPSC recurrences. Adriamycin, cytoxan, & cisplatin bought an average 7 months of remission for recurrent OVARIAN serous cancer women.

Current 'gold standard' for recurrent UPSC:
1.) surgery to reduce residual disease to less than 2 CM.
2.) TAP (paciltaxel + cisplatin + doxorubicin
3.) tumor-directed radiation
This 'gold standard' does not increase recurrence-free survival, but DOES increase progression free survival by 8.3 months. It has a high rate of neurotoxicity.

Sandwiched radiation has been shown to be statistically better than radiation-then-chemo, or chemo-then-radiation.

UPSC women with CA-125s greater than 35 BEFORE surgery have 3.7 times greater risk of cancer-related death than those with CA-125s under 35 before surgery. (Good news for those of you who have always had low CA-125s. Not so good for us that had tp bring our CA-125s down with chemo.)

Indicators in addition to CA-125s that could/should be looked at in the future for UPSC include serum markers like HE4 (a soluble mesothelin-related peptide) and YKL-40 (a secreted glycolprotein).

Herceptin has not yet been studied for UPSC women with HER2, but looks promising.

The article recommended an 'international rare cancer cooperative network' study of UPSC.

THANK YOU, Linda,
THANK YOU, Linda,

Appreciate your work!!! I don't like the CA 125 news!!!

Mary Ann